Prostate Cancer
Conditions
Interventions
Experimental group:bipolar androgen therapy
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. ECOG score =18 years; 3. Pathological findings suggested prostate adenocarcinoma; 4. Progress after treatment of persistent androgen deprivation (surgical castration/drug castration); 5. Serum testosterone was castrated (<50 ng/dl); 6. Patients must have been treated with docetaxel and abiraterone acetate in the past and have subsequently developed disease progression (as determined by PSA criteria or radiological examination); 7. PSA elevation was measured twice in succession with an interval of at least two weeks; 8. The patient understands and is willing to sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Use opioid painkillers to control the pain caused by metastatic prostate cancer; 2. There are more than 5 metastatic foci in the lungs or liver; 3. Secondary urinary tract obstruction caused by prostatic hyperplasia or prostate cancer requires urinary catheterization; 4. Researchers believe that testosterone therapy increases the risk of disease occurrence in certain areas or degrees (e.g., femoral metastasis is related to fracture risk, spinal metastasis is related to spinal cord compression, and lymph node disease is related to ureteral obstruction); 5. Previously severe/unstable medical, psychiatric or other conditions (including laboratory abnormalities) that may interfere with the patient's safety or provide informed consent to participate in the study; 6. Any psychological, family, sociological or geographical conditions that may affect their compliance with the research plan and follow-up work; 7. There is a previous history of thromboembolism in the past two years, and there is no systemic anticoagulation therapy at present.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA drops by half;PSA progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| clinical/radiogarphical progression free survival;quality of life; | — |
Countries
China
Contacts
Public ContactYang Lu
West China Hospital, Sichuan University
Outcome results
None listed